Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma.
The prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma (GC) has been widely reported and is still under debate. Here, we evaluated the prognostic significance of preoperative serum CA125, CA19-9 and CEA in patients with GC. 1692 patients with GC who underwent gastrectomy were divided into the training (from January 2005 to December 2011, n = 1024) and the validation (from January 2012 to December 2013, n = 668) cohorts. Positive groups of CA125 (> 13.72 U/ml), CA19-9 (> 23.36 U/ml) and CEA (> 4.28 ng/ml) were significantly associated with more advanced clinicopathological traits and worse outcomes than that of negative groups (all P < 0.01). In Cox regression analysis, tumor size (P < 0.001, P = 0.005), pTNM stage (P < 0.001, P < 0.001) and CA125 (P = 0.026, P = 0.005) were independent prognostic factors both in two cohorts. Nomograms of these two cohorts based on the number of positive serum tumor markers (NPTM) were more accurate in prognostic prediction than TNM stage alone. Our findings suggested that elevated preoperative serum CA125, CA19-9 and CEA were associated with more advanced clinicopathological traits and less favorable outcomes. In addition, CA125 as an independent prognostic factor should be further investigated. Nomogram based on NPTM could accurately predict the prognosis of GC patients.
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.|Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Wei
W
Wang
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.|Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Xiao-Long
XL
Chen
West China School of Medicine, Sichuan University, Chengdu, China.
Shen-Yu
SY
Zhao
West China School of Medicine, Sichuan University, Chengdu, China.
Yu-Hui
YH
Xu
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.|Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Wei-Han
WH
Zhang
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.|Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Kai
K
Liu
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.|Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Xin-Zu
XZ
Chen
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.|Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Kun
K
Yang
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.
Bo
B
Zhang
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.
Zhi-Xin
ZX
Chen
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.
Jia-Ping
JP
Chen
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.|Laboratory of Digestive Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Zong-Guang
ZG
Zhou
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.|Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Jian-Kun
JK
Hu
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D002277:Carcinoma / Q000097:blood / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology*
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins
CA125; CA19-9; CEA; gastric cancer; tumor marker